<DOC>
	<DOCNO>NCT02471898</DOCNO>
	<brief_summary>A Phase 2 , Randomized , Double-Blind , Placebo-Controlled , Two-Part Evaluation Efficacy Safety Locally Administered HTX-011 Postoperative Analgesia Following Bunionectomy</brief_summary>
	<brief_title>A Phase 2 , Two-Part Evaluation Efficacy Safety Locally Administered HTX-011 Postoperative Analgesia Following Bunionectomy</brief_title>
	<detailed_description />
	<criteria>1 . Voluntarily provide write informed consent . 2 . Male female 18 65 year age , inclusive . 3 . Be schedule undergo primary unilateral first metatarsal bunionectomy repair , without collateral procedure , regional anesthesia 4 . Be American Society Anesthesiology ( ASA ) physical Class 1 2 . 5 . Female subject eligible follow apply : Not pregnant ( female subject child bear potential must negative serum pregnancy test screen negative urine pregnancy test surgery ) ; Not lactate Not plan become pregnant study Be surgically sterile ; least two year postmenopausal ; monogamous partner surgically sterile ; practice doublebarrier contraception ; practice abstinence ( must agree use doublebarrier contraception event sexual activity ) ; use insertable , injectable , transdermal , combination oral contraceptive approve FDA great 2 month prior screen visit commits use acceptable form birth control duration study 30 day completion study . 6 . Male patient must surgically sterile ( biologically surgically ) commit use reliable method birth control duration study least 1 week administration study medication . 7 . Have body mass index â‰¤ 35 kg/m2 . 8 . Be able understand study procedure , comply study procedure , agree participate study program . 9 . Be able understand communicate English . 1 . Have know allergy Bupivacaine/Meloxicam HTX011/placebo excipient peri postoperative medication use study include oxycodone lidocaine , propofol , fentanyl , midazolam . 2 . Have clinically significant abnormal clinical laboratory test value accord judgment investigator . 3 . Have history positive test result HIV hepatitis B C screening . 4 . Have , determine investigator study 's medical monitor , history clinical manifestation significant renal , hepatic , cardiovascular , metabolic , neurologic , psychiatric , condition would preclude participation study . 5 . Have history migraine frequent headache , seizure , currently take anticonvulsant . 6 . Have another painful physical condition , opinion investigator , may confound assessment postoperative pain . 7 . Have receive receive chronic opioid therapy define great 15 morphine equivalent unit per day great 3 7 day per week onemonth period within 12 month study treatment initiation . 8 . Use concurrent therapy could interfere evaluation efficacy safety , drug investigator 's opinion may exert significant analgesic property act synergistically HTX01119 . 9 . Have evidence clinically significant 12lead ECG abnormality accord judgment investigator . 10 . Have history alcohol abuse ( regularly drink &gt; 4 unit alcohol per day ; 8 oz . beer , 3 oz . wine , 1 oz . spirit ) prescription/illicit drug abuse . 11 . Have positive result alcohol breath test indicative alcohol abuse urine drug screen indicative illicit drug use ( unless result explain current prescription acceptable overthecounter medication screening determine investigator ; however , urine drug screen prior surgery must negative ) screening , and/or prior surgery . 12 . Unable discontinue medication stable dose least 14 day prior schedule bunionectomy procedure , within 5 halflives specific prior medication ( , halflife know , within 48 hour ) dose study medication . 13 . Have utilized corticosteroid , either systemically , inhale either intranasally orally , intraarticular injection , within 14 day prior study surgical procedure . 14 . Have receive investigational product within 30 day dose study medication . 15 . Have previously receive HTX01119 clinical trial bunionectomy last 3 month . 16 . Experiences clinically significant event surgery prior administration investigational product ( e.g. , excessive bleeding , hemodynamic instability ) would render subject medically unstable , complicate postsurgical course , significantly increase risk study drug administration per judgment investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>